BCA
NGM

Berman Capital Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Berman Capital Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Hold
57
– – ﹤0.01% 2014
2021
Q2 		$1K Buy
+57
New +$1.33K ﹤0.01% 1844
2020
Q3 		– Sell
-91
Closed -$1K – 1818
2020
Q2 		$1K Buy
+91
New +$1.74K ﹤0.01% 1543

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Berman Capital Advisors's NGM Position: Q3 2021 in Review

Berman Capital Advisors held its NGM Biopharmaceuticals, Inc. Common Stock (NGM) position steady in Q3 2021 at 57 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2014.

Berman Capital Advisors first reported a position in NGM in Q2 2020 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

  • Berman Capital Advisors held 57 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $1K as of Q3 2021.
  • Berman Capital Advisors left its NGM Biopharmaceuticals, Inc. Common Stock share count unchanged in Q3 2021.
  • NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2014 holding.
  • Berman Capital Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.